Patients enrolled in the two-arm study were randomized aftersurgery to receive either FOLFOX chemotherapy alone for six months or FOLFOX

Patients enrolled in the two-arm study were randomized aftersurgery to receive either FOLFOX chemotherapy alone for six months or FOLFOX incombination with Avastin (intravenous every two weeks) for six months, followedby an additional six months of Avastin monotherapy The secondary endpoint ofthe study was overall survival. About the Avastin Development ProgramResults are expected in 2010 from a separate Roche-sponsored international PhaseIII study (AVANT) assessing Avastin in combination with chemotherapy forearly-stage colon cancer. The three-arm trial is evaluating Avastin incombination with the chemotherapy regimens XELOX (capecitabine and oxaliplatin)or FOLFOX chemotherapy versus FOLFOX alone. In addition to early-stage colon cancer, Avastin is being studied as an adjuvanttreatment in other early-stage diseases: HER2-negative breast cancer,HER2-positive breast cancer and non-squamous, non-small cell lung cancer.Approximately 26,000 people are expected to participate in Avastin adjuvantstudies. The Avastin development program represents one of the most comprehensiveundertakings in cancer research since chemotherapy and includes more than 450clinical trials worldwide in approximately 30 different tumor types. About AvastinAvastin is a biologic antibody designed to specifically inhibit the vascularendothelial growth factor (VEGF) protein that plays an important role in thedevelopment and maintenance of blood vessels, a process known as angiogenesis.VEGF is a potent activator of angiogenesis throughout the lifecycle of a tumorand is thought to be critical to a tumor's ability to grow and spread in thebody (metastasize). Avastin is indicated for the first- and second-linetreatment of metastatic colorectal cancer in combination with intravenous5-FU-based chemotherapy and for the first-line treatment of unresectable,locally advanced, recurrent or metastatic non-squamous NSCLC in combination withcarboplatin and paclitaxel.

About Avastin in Metastatic Colorectal CancerAvastin in combination with IV 5-FU-based chemotherapy was proven to extendoverall survival by 52 percent compared to chemotherapy alone in people withadvanced colorectal cancer. This is one of the largest improvements in survivalever reported in a randomized Phase III advanced colorectal cancer study (hazardratio 0.66). In a Phase III study in second-line advanced colon cancer, Avastinin combination with FOLFOX4 chemotherapy improved overall survival by 33 percentcompared to chemotherapy alone (hazard ratio 0.75). Avastin SafetyThe most serious side effects associated with Avastin, in some cases resultingin death, across all trials were gastrointestinal (GI) perforation (thedevelopment of a hole in the stomach, small intestine, or large intestine), slowwound healing, severe bleeding, and blood clots. Additional serious side effectsare formation of an abnormal passage from parts of the body to another part,severe high blood pressure, nervous system and vision disturbances, reducedwhite blood cell counts, kidney problems, and congestive heart failure.Treatment with Avastin can also result in slow wound healing and in some casescan cause the wound to reopen. The most common serious adverse events across different cancer types were highblood pressure, blood clots, stroke, reduced white blood cell counts, infection,bleeding, weakness, abdominal pain, pain, headache, tiredness, a brief loss ofconsciousness, diarrhea, constipation, blockage of the bowel, nausea, vomiting,dehydration, numbness and tingling in fingers and toes, and too much protein inthe urine.

Patients receiving Avastin should have their blood pressure monitoredevery 2 to 3 weeks Avastin may cause problems getting pregnant. People who are pregnant or thinkingof becoming pregnant should talk with their doctor about the potential risks ofloss of pregnancy or the potential risk of Avastin to the fetus. Nursing mothersshould not breast-feed while receiving Avastin, or for a short period of timeafter treatment is finished. Please visit http:// for the Avastin full prescribing information,including Boxed WARNINGS and additional important safety information. About GenentechFounded more than 30 years ago, Genentech is a leading biotechnology companythat discovers, develops, manufactures and commercializes medicines to treatpatients with serious or life-threatening medical conditions.

The company, awholly-owned member of the Roche Group, has headquarters in South San Francisco,California. For additional information about the company, please visit http:// Genentech, Inc.Megan Pace, 650-467-7334 (Media)Kathee Littrell, 650-225-1034 (Investors)Kristin Reed, 650-467-9831 (Advocacy) Copyright Business Wire 2009.  So many people have criticized Dallas Cowboys safety, Roy Williams for being “bad.”I completely understand your thinking.There are times when I myself a Cowboys fan have been praying that the quarterback does not throw the ball in his direction.  Moreover, for all the things he does wrong, he doesn’t do what he does, to the best of his ability.  You may remember when Williams was a rookie he laid the wood.  Receivers shivered at the thought of running a post pattern in his vicinity.  Running backs would hold onto the football tighter than if it were the last dollar they had to their name.  However, now players view him as a joke  Don't get me wrong, Cowboys fans. I am in no way bashing Roy.  All I'm saying is pick it up Roy.Now Roy I say to you:Football can always be taught.  Hit the film room with Zach Thomas, get together with Campo and learn.  The ability is there, it doesn’t just go away.All of this "I don't fit in this scheme” mumbo jumbo is crap.  You adjust to the game.  You have to make it work for you.  Sure the NFL is cracking down on big hits, but come on man, at least wrap up the ball carrier.This season is supposedly your “make or break” year I truly don't buy that.